Last reviewed · How we verify
Capecitabine, 5-fluorouracil prodrug; oral
Capecitabine, 5-fluorouracil prodrug; oral is a Small molecule drug developed by Array Biopharma, now a wholly owned subsidiary of Pfizer. It is currently in Phase 1 development.
At a glance
| Generic name | Capecitabine, 5-fluorouracil prodrug; oral |
|---|---|
| Sponsor | Array Biopharma, now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma (PHASE2)
- CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) (PHASE2)
- A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer (PHASE2)
- Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer (PHASE1, PHASE2)
- A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer (PHASE1)
- Chemotherapeutic Agents in Brain/Breast
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine, 5-fluorouracil prodrug; oral CI brief — competitive landscape report
- Capecitabine, 5-fluorouracil prodrug; oral updates RSS · CI watch RSS
- Array Biopharma, now a wholly owned subsidiary of Pfizer portfolio CI
Frequently asked questions about Capecitabine, 5-fluorouracil prodrug; oral
What is Capecitabine, 5-fluorouracil prodrug; oral?
Capecitabine, 5-fluorouracil prodrug; oral is a Small molecule drug developed by Array Biopharma, now a wholly owned subsidiary of Pfizer.
Who makes Capecitabine, 5-fluorouracil prodrug; oral?
Capecitabine, 5-fluorouracil prodrug; oral is developed by Array Biopharma, now a wholly owned subsidiary of Pfizer (see full Array Biopharma, now a wholly owned subsidiary of Pfizer pipeline at /company/array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer).
What development phase is Capecitabine, 5-fluorouracil prodrug; oral in?
Capecitabine, 5-fluorouracil prodrug; oral is in Phase 1.